Suzhou Novoprotein Scientific Co. Ltd. A
Novoprotein Scientific Inc. researches, develops, produces, and sells raw materials and technical solutions for bio-pharmaceutical enterprises and research institutions in Asia, Europe, the United States, and Oceania. It offers cytokines, target proteins, mRNA vaccine and drug enzymes, recombinant antibodies, enzymes and reagents, biosimilar reference antibodies, gene and cell therapy, molecular … Read more
Suzhou Novoprotein Scientific Co. Ltd. A (688137) - Total Liabilities
Latest total liabilities as of June 2025: CN¥116.44 Million CNY
Based on the latest financial reports, Suzhou Novoprotein Scientific Co. Ltd. A (688137) has total liabilities worth CN¥116.44 Million CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Suzhou Novoprotein Scientific Co. Ltd. A - Total Liabilities Trend (2020–2024)
This chart illustrates how Suzhou Novoprotein Scientific Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Suzhou Novoprotein Scientific Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Suzhou Novoprotein Scientific Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Deep Value Driller AS
OL:DVD
|
Norway | Nkr103.56 Million |
|
Man Industries (India) Limited
NSE:MANINDS
|
India | ₹20.84 Billion |
|
Taigen Biopharmaceuticals Holdings Ltd
TWO:4157
|
Taiwan | NT$120.70 Million |
|
Randon S.A. Implementos e Participações
SA:RAPT3
|
Brazil | R$13.73 Billion |
|
Savencia SA
PINK:BNGRF
|
USA | $3.08 Billion |
|
LITALICO Inc.
F:9N0
|
Germany | €26.72 Billion |
|
Kung Sing Engineering Corp
TW:5521
|
Taiwan | NT$7.66 Billion |
|
Nexpoint Real Estate Finance Inc
NYSE:NREF
|
USA | $4.49 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down Suzhou Novoprotein Scientific Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 25.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Suzhou Novoprotein Scientific Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Suzhou Novoprotein Scientific Co. Ltd. A (2020–2024)
The table below shows the annual total liabilities of Suzhou Novoprotein Scientific Co. Ltd. A from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥116.44 Million | +5.45% |
| 2023-12-31 | CN¥110.43 Million | -17.11% |
| 2022-12-31 | CN¥133.22 Million | -13.11% |
| 2021-12-31 | CN¥153.33 Million | +87.69% |
| 2020-12-31 | CN¥81.69 Million | -- |